Attention-deficit/hyperactivity disorder (ADHD) is one of the most common childhood disorders and one that can continue into adulthood. For decades, pediatric ADHD has been treated primarily with psychostimulants, and numerous convenient, once-daily, long-acting psychostimulants in a variety of distinct formulations are now available in the United States. However, the FDA classifies psychostimulants as controlled substances because of the potential for abuse. Although nonstimulant therapies have become key therapeutic alternatives, a lingering perception of their less-robust efficacy versus that of psychostimulants has enabled psychostimulants to maintain a strong presence in the treatment algorithm for pediatric ADHD.
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world patient-level claims data so that you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Eli Lilly, Janssen, Novartis, Pfizer, Shire
Key drugs: Atomoxetine (Strattera, generics), guanfacine ER (Intuniv, generics), methylphenidate ER (Concerta, generics), Quillichew ER, Ritalin LA, Vyvanse
Key analysis provided: